Diabetic kidney disease (DKD) is a major complication of T1D. To better understand the risks of developing DKD, we evaluated risk factors in participants from the T1D Exchange registry who completed 5-year follow-up. Participants had at least two eGFR and albuminuria measurements recorded during the 5 year period; also T1D duration ≥1 year, age ≥10 years, eGFR ≥60 ml/minute and no documented albuminuria at enrollment. Adverse kidney outcomes were defined as eGFR <60 ml/minute and/or micro/macroalbuminuria (micro/macroALB) at any follow-up visit. Univariate chi-square tests, Wilcoxon tests and multivariate logistic regression were used to determine associations between adverse kidney outcomes and risk factors. Among 3,296 participants (mean age 41 ± 15 years, T1D duration 21± 13 years, mean HbA1c 7.6 ± 1.2%, 91% white non-Hispanic,56% female at enrollment) with valid data, 547 (16.6%) experienced an adverse kidney outcome during 5-year follow-up: 224 (6.8%) experienced micro/macroALB while eGFR remained ≥60 ml/minute, 274 (8.3%) had a decline in eGFR to <60 ml/minute without micro/macroALB, and 49 (1.5%) experienced eGFR <60 ml/minute with micro/macroALB. Higher HbA1c, higher SBP, lower DBP as well as older age and lower education level were the significant risk factors for the development of an adverse kidney outcome over 5 years (Table). Control of risk factors and better glycemic control may minimize future DKD.

J.B. McGill: Research Support; Self; AstraZeneca. Consultant; Self; Boehringer Ingelheim GmbH. Speaker's Bureau; Self; Aegerion Pharmaceuticals. Consultant; Self; Bayer AG, Dexcom, Inc., Intarcia Therapeutics, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc., MannKind Corporation. Research Support; Self; Novartis Pharmaceuticals Corporation. Consultant; Self; Novo Nordisk A/S. M. Wu: None. R. Pop-Busui: Research Support; Self; AstraZeneca. K.R. Mizokami-Stout: None. W.V. Tamborlane: Consultant; Self; AstraZeneca, Boehringer Ingelheim GmbH, Eli Lilly and Company, Medtronic MiniMed, Inc., Novo Nordisk Inc., Sanofi, Takeda Pharmaceuticals U.S.A., Inc. G. Aleppo: Research Support; Self; AstraZeneca, Novo Nordisk Inc.. Consultant; Self; Dexcom, Inc.. Advisory Panel; Self; Novo Nordisk Inc.. R. Gubitosi-Klug: None. M.J. Haller: None. S.M. Willi: Advisory Panel; Self; Boehringer Ingelheim GmbH. Other Relationship; Self; Caladrius Biosciences, Inc.. Consultant; Self; GlaxoSmithKline plc., JAEB Center For Health Research. N.C. Foster: None. C. Zimmerman: None. I. Libman: Consultant; Self; Novo Nordisk A/S. S. Polsky: Research Support; Self; Dexcom, Inc.. Other Relationship; Self; T1D Exchange. Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases. M.R. Rickels: Consultant; Self; Hua Medicine, Xeris Pharmaceuticals, Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.